THE TRENDLINES GROUP LTD.
(Incorporated in Israel)
(Company Registration No. 513970947)
Condensed Interim Financial Statements
For the Six Months and Full Year Ended 31 December 2021
Background
The Trendlines Group Ltd. (the "Company" or "Trendlines" and, together with its subsidiaries and associated companies, the "Group") was incorporated on 1 May 2007 as a private company limited by shares under the Israeli Companies Law.
The Group is focused on developing technology-based companies in the medical and agrifood fields. The Group creates and develops companies in accordance with the mission to improve the human condition. To this end, the Group discovers, invests in, incubates and provides services to companies in the fields of medical and agricultural technologies with a view toward a successful exit in the marketplace. Exits may include sales such as merger and acquisition transactions, listing on public stock exchanges and other dispositions of the Company's holdings.
The Group also has its own internal innovation centre, Trendlines Innovation Labs (established as a business unit of the Company in 2011), where it engages in research and development activities to create new technologies, either as principal or in collaboration with global and local companies and partners, to address unmet market needs.
Furthermore, Trendlines Innovation Labs' technologies can be sold or licensed to others or transfered to Trendlines' incubators for further development and commercialization.
PART I - Condensed Interim Financial Statements and Selected Notes to the Condensed Interim Financial Statements
1(a)(i) A condensed interim income statement and statement of comprehensive incomes/loss, or a statement of comprehensive income/loss (for the Group) together with a comparative statement for the corresponding period of the immediately preceding financial year.
Group | |||||||
6 months | 6 months | 12 months 12 months | |||||
ended 31 | ended 31 | ended 31 | ended 31 | ||||
December | December | December December | |||||
2021 | 2020 | 2021 | 2020 | ||||
(Unaudited) | (Unaudited) | Change | (Unaudited) | (Audited) | Change | ||
US$'000 | US$'000 | (%) | US$'000 | US$'000 | (%) | ||
Income: | |||||||
Gain / (loss) from change in fair value of | |||||||
investments in Portfolio Companies, net | 2,961 | (7,370) | N.M. | 9,151 | (10,996) | N.M. | |
Income from services to Portfolio | |||||||
Companies | 777 | 1,182 | (34.26) | 1,542 | 2,981 | (48.27) | |
Income from contracted R&D services | 391 | 521 | (24.95) | 759 | 863 | (12.05) | |
Financial income | 660 | 2,246 | (70.61) | 4,260 | 3,931 | 8.37 | |
Other income | 239 | 347 | (31.12) | 410 | 372 | 10.22 | |
Totalincome / (loss) | 5,028 | (3,074) | N.M. | 16,122 | (2,849) | N.M. | |
Expenses | |||||||
Operating, general and administrative | |||||||
expenses | 6,266 | 4,564 | 37.29 | 11,125 | 7,937 | 40.15 | |
Marketing expenses | 152 | 118 | 28.81 | 328 | 214 | 53.27 | |
R&D expenses, net | 806 | 594 | 35.69 | 1,510 | 1,087 | 38.91 | |
Financial expenses | (464) | 454 | N.M. | 514 | 860 | (40.23) | |
Totalexpenses | 6,760 | 5,730 | 17.97 | 13,477 | 10,098 | 33.46 | |
Income / (loss) before income taxes / | |||||||
(tax benefit) | (1,732) | (8,804) | (80.32) | 2,645 | (12,947) | N.M. | |
tax benefit | 3,679 | 8,961 | 58.93 | 3,355 | 8,996 | (62.69) | |
Net income / ( loss) | 1,947 | 157 | 1140.12 | 6,000 | (3,951) | N.M. | |
Other comprehensive loss: | |||||||
Amounts that will be or that have been | |||||||
reclassified to profit / loss when specific | |||||||
conditions are met: | |||||||
Income / (loss) from cash flow hedges | - | 594 | N.M. | (45) | 220 | N.M. | |
Total comprehensive income / (loss) | 1,947 | 751 | 159.25 | 5,955 | (3,731) | N.M. |
2
Net income (loss) attributable to: Equity holders of the Company Non-Controlling Interests
Total comprehensive income / (loss) attributable to:
Equity holders of the Company Non-Controlling Interests
Net income / (loss) per share attributable to equity holders of the Company (U.S. cents):
Basic net income / (loss)
Diluted net income / (loss)
2,193 | 360 | 509.16 | 6,563 | (3,734) | N.M. |
(246) | (203) | 21.18 | (563) | (217) | 159.45 |
1,947 | 157 | 1140.12 | 6,000 | (3,951) | N.M. |
2,193 | 954 | 129.87 | 6,518 | (3,514) | N.M. |
(246) | (203) | 21.18 | (563) | (217) | (159.45) |
1,947 | 751 | 159.25 | 5,955 | (3,731) | N.M. |
0.29 | 0.05 | 543.33 | 0.83 | (0.47) | N.M. |
0.29 | 0.05 | 543.33 | 0.83 | (0.47) | N.M. |
1(a)(ii) Notes to Condensed Interim Consolidated Statement of Comprehensive income/(loss)
31 December 2021 | 31 December 2020 | |
(Unaudited) | (Audited) | |
US$'000 | US$'000 | |
Depreciation, amortization and | ||
impairment loss | 1,102 | 1,356 |
Foreign currency exchange loss | (48) | (647) |
N.M. denotes Not Meaningful |
3
1(b)(i) A condensed interim statement of financial position (for the issuer and Group), together with a comparative statement as at the end of the immediately preceding financial year
Group | Company | |||
31 December | 31 December 31 December | 31 December | ||
2021 | 2020 | 2021 | 2020 | |
(Unaudited) | (Audited) | (Unaudited) | (Audited) | |
US$'000 | US$'000 | US$'000 | US$'000 | |
Assets | ||||
Current assets | ||||
Cash and cash equivalents | 14,309 | 10,656 | 10,894 | 2,199 |
Short-term bank deposits | 4,252 | 101 | 4,149 | - |
Accounts and other receivables | 3,361 | 2,698 | 8,301 | 1,125 |
Short-term loans to Portfolio | ||||
Companies | 287 | 19 | 225 | - |
22,209 | 13,474 | 23,569 | 3,324 | |
Non-current assets | ||||
Investment in Subsidiaries | - | - | 78,352 | 82,911 |
Long-term bank deposits | - | 4,127 | - | 4,127 |
Accounts and other receivables | 5,276 | 2,696 | 4,721 | - |
Contingent consideration receivable | 6,599 | 2,898 | 6,599 | - |
Investments in Portfolio Companies | 83,046 | 83,730 | - | - |
Deferred taxes | - | 6,838 | - | 6,645 |
Right of use asset | 2,752 | 2,122 | - | - |
Property, plant and equipment, net | 1,201 | 959 | 523 | 130 |
98,874 | 103,370 | 90,195 | 93,813 | |
Total assets | 121,083 | 116,844 | 113,764 | 97,137 |
EQUITY AND LIABILITIES | ||||
Current liabilities | ||||
Lease liability | 776 | 669 | - | - |
Short-term loan | 4,241 | - | 4,241 | - |
Trade and other payables | 4,246 | 1,679 | 2,204 | 596 |
Deferred revenues | 1,184 | 616 | 337 | - |
10,447 | 2,964 | 6,782 | 596 | |
Non-current liabilities | ||||
Loans from the Israel Innovation | ||||
Authority | 2,718 | 2,626 | 1,434 | - |
Deferred revenues | 679 | - | - | - |
Lease liability | 2,274 | 2,297 | - | - |
Deferred taxes | 2,156 | 12,350 | 2,230 | |
Other long-term liabilities | 267 | 272 | 232 | 223 |
8,094 | 17,545 | 3,896 | 223 |
4
Total liabilities | 18,541 | 20,509 | 10,678 | 819 |
Equity | |||||
Equity Attributable to Equity | |||||
Holders of the Company: | |||||
Share capital | 2,123 | 2,123 | 2,123 | 2,123 | |
Share premium | 79,312 | 79,307 | 79,312 | 79,307 | |
Reserve from hedge | - | 45 | - | 45 | |
Reserve from share-based payment | |||||
transactions | 4,378 | 4,131 | 4,378 | 4,131 | |
Retained earnings | 17,273 | 10,710 | 17,273 | 10,710 | |
Equity attributable to owners of | |||||
the parent | 103,086 | 96,316 | 103,086 | 96,316 | |
Non-controlling interests | (544) | 19 | - | - | |
Total equity | 102,542 | 96,335 | 103,086 | 96,316 | |
Total equity and liabilities | 121,083 | 116,844 | 113,764 | 97,137 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Trendlines Group Ltd. published this content on 22 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2022 13:01:00 UTC.